\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes EICUPDATE: the call deadline has been postponed to 30 September 2021 12:00 Brussels time
A call for expression of interest for European Innovation Council (EIC) Programme Managers is currently open. The European Innovation Council and SMEs Executive Agency (EISMEA) aims to establish a reserve list of approximately 15 candidates and to recruit up to 6 candidates.
Apart from funding for research and innovation the EIC has as objective to turn technological breakthroughs out of their (portfolios of) funded projects into business opportunities. The EIC Programme Managers have an important role in guiding this process. EIC Programme Managers are experts in emerging science and technology areas.
In 2019 the first four EIC programme managers were recruited in the areas of health and biotechnology, medical technologies and medical devices, materials for energy and environmental sustainability, innovation management and energy systems and green technologies. The new programme managers are expected to have expertise in other thematic areas. Women are encouraged to apply.
All information on the call for EoI can be found in this EIC news article.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
